Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Summary

This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.

Timeline

Start

2016-01

Primary completion

2017-12

Completion

2017-12

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs RVT-101 35 mg; p = 0.158; NCT02669433 ↗

registry analysis (superiority test); Placebo vs RVT-101 70 mg; p = 0.6069; NCT02669433 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	intepirdine	Small molecule	35 mg	Oral
Subject	intepirdine	Small molecule	70 mg	Oral

Indications